| Literature DB >> 24098707 |
Nadia N Abuelezam1, Kathryn Rough, George R Seage.
Abstract
BACKGROUND: Individual-based modeling is a growing technique in the HIV transmission and prevention literature, but insufficient attention has been paid to formally evaluate the quality of reporting in this field. We present reporting recommendations for individual-based models for HIV treatment and prevention, assess the quality of reporting in the existing literature, and comment on the contribution of this model type to HIV policy and prediction.Entities:
Mesh:
Year: 2013 PMID: 24098707 PMCID: PMC3787035 DOI: 10.1371/journal.pone.0075624
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Recommended reporting guidelines for individual-based models of HIV transmission and prevention .
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Title and Abstract | 1 | Identify in the title or abstract that the analysis depends on an | |||||||
| Objective | 2 | State the objectives of the analysis with specific reference to the population(s), intervention(s), and time period(s) of interest. | |||||||
| Context | 3 | Justify the exploration of the policy question in the context of previous trials, cohorts, and modeling analyses for the time period(s) of interest. | |||||||
| Model Justification | 4 |
| |||||||
|
| |||||||||
| Structure | 5 | Describe the model’s structure in both words and figures and describe how it affords the ability to explore the question(s) of interest. | |||||||
| Assumptions | 6 | State the assumptions implicit in the model structure and justify with knowledge and data from the population of interest. | |||||||
| Validity of Sexual Behavior | 7 | Justify the validity of the necessary behavior accounted for in the model. | |||||||
| Validity of Biology | 8 | Justify the validity of the necessary biology accounted for in the model. | |||||||
|
| |||||||||
| Parameters | 9 | List fixed parameters and calibrated parameters with ranges justified by the literature. | |||||||
| Time step | 10 |
| |||||||
| Heterogeneity | 11 |
| |||||||
| Interaction | 12 | Describe the parameters used to implement individual interaction in the model and justify the data used to parameterize these parameters. | |||||||
|
| |||||||||
| Calibration | 13 |
| |||||||
| Sensitivity Analyses | 14 | Summarize the results of sensitivity analyses on the main model parameters, discuss whether the results support the robustness of findings, and describe future work needed. | |||||||
| Assumption Sensitivity | 15 | Discuss how the behavior and inference of the model changes when particular assumptions ( | |||||||
| Stochastic Sensitivity | 16 |
| |||||||
| Internal Validity | 17 |
| |||||||
|
| |||||||||
| Data Quality | 18 | Describe the quantity and quality of the data used to inform parameters for the population(s) of interest. | |||||||
| Data Conversion | 19 |
| |||||||
| Results | 20 | Present key modeling results with uncertainty estimates and | |||||||
| Limitations and Strengths | 21 | Provide the key limitations and strengths of the modeling study. | |||||||
| Reproducibility | 22 | Discuss whether the model is able to reproduce the behavior of other populations or interventions of interest. | |||||||
| Discussion | 23 | Interpret the modeling analysis within realistic bounds, with reference to previous modeling studies, a discussion about the generalizability of the modeling results, and implications for future studies or models. | |||||||
|
| |||||||||
| Authorship and Funding | 24 | List sources of funding and describe each author’s contribution to the modeling framework and conceptualization. | |||||||
Bolded guidelines are specific to individual-based models of HIV transmission and prevention. Non-bolded guidelines are adaptable across different types of models.
Figure 1Cascade of papers excluded and included in the systematic review of individual-based HIV transmission, treatment, and prevention models in the literature.
Information on the 32 papers describing individual-based HIV treatment models that passed the inclusion criteria.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Adams et al. [ | 1998 | Simulation | HIVSIM | Men who have sex with men (MSM) or heterosexual adults | No | Vaccine |
| Amirfar et al. [ | 2006 | JAIDS | 15-25 year old South African adolescent and adult females and their infants | Yes | Vaccine/PMTCT | |
| Atkinson, J [ | 1996 | Comput Biomed Res | Injection drug users (IDU) | No | Behavioral | |
| Bendavid et al. [ | 2010 | Arch Intern Med | Heterosexual adult South Africans | Yes | Testing/Treatment | |
| Bernstein et al. [ | 1998 | Interfaces | SimulAIDS | Heterosexual adults in a generic east African city | No | Behavioral/STD testing |
| Beyrer et al. [ | 2012 | Lancet | MSM residing in high (urban USA), middle (urban Peru), and low income countries | Yes | Behavioral | |
| Bracher et al. [ | 2004 | Stud Fam Plann | Heterosexual adults in rural southern Malawi | No | Behavioral | |
| Enns and Brandeau [ | 2011 | Health Care Manag Sci | Heterosexual Tanzanian adults | Yes | Behavioral | |
| Freeman et al. [ | 2009 | Vaccine | STDSIM | Heterosexual adults in Sub-Saharan Africa | No | STD vaccine |
| Gray et al. [ | 2003 | AIDS | Gray | Heterosexual adult discordant Ugandan couples | Yes | Treatment/Vaccine |
| Gray et al. [ | 2007 | AIDS | Gray | Heterosexual adult discordant Ugandan couples | No | Male circumcision |
| Gray et al. [ | 2011 | Vaccine | MSM in NSW, Australia | Yes | Vaccine | |
| Hallett et al. [ | 2011 | PLoS Med | Stable HIV-1 serodiscordant heterosexual couples in South Africa | Yes | PrEP | |
| Hallett et al. [ | 2011 | Sex Transm Infect | MSM in the Netherlands | Yes | Behavioral/Testing | |
| Hoare et al. [ | 2012 | Sex Health | MSM in Victoria, Australia | Yes | Testing | |
| Hontelez et al. [ | 2011 | Vaccine | STDSIM | Heterosexual adults in a rural South African setting | Yes | Vaccine |
| Hontelez et al. [ | 2012 | AIDS | STDSIM | Heterosexual adults in Sub-Saharan Africa | Yes | Treatment |
| Korenromp et al. [ | 2000 | AIDS | STDSIM | Heterosexual adults in Mwanza, Tanzania | No | STD treatment |
| Korenromp et al. [ | 2002 | AIDS | STDSIM | Heterosexual adults in Rakai, Uganda | No | STD treatment |
| Korenromp et al. [ | 2005 | J Infect Dis | STDSIM | Heterosexual adults in Rakai and Masaka, Uganda and Mwanza, Tanzania | No | STD treatment |
| Marshall et al. [ | 2012 | PLoS One | IDU/NIDU/MSM in the New York metropolitical statistical area | Yes | Behavioral/Testing | |
| McCabe et al. [ | 2010 | PLoS One | Pregnant women and infants in the United States | Yes | PMTCT | |
| McCreesh et al. [ | 2011 | Sex Transm Infect | Heterosexual adults in rural South-West Uganda | Yes | Behavioral | |
| Rauner et al. [ | 2005 |
| Pregnant women and infants in Tanzania | Yes | PMTCT | |
| Robinson et al. [ | 1995 | AIDS | SimulAIDS | Heterosexual adults in rural south-west Uganda | No | Behavioral/STD treatment |
| Van der Ploeg et al. [ | 1998 | Interfaces | STDSIM | Heterosexual adults in Nairobi, Kenya | No | Behavioral/STD treatment |
| van Vliet et al. [ | 2001 | Bull World Health Organ | STDSIM | Heterosexual adults | No | Behavioral |
| Vieira et al. [ | 2010 | Ann. Oper Res | Urban heterosexual, MSM, and bisexual adult Brazilians | Yes | Treatment/Vaccine/Behavioral | |
| Vissers et al. [ | 2011 | Epidemiol Infect | STDSIM | Heterosexual adults in Tanzania | No | Behavioral |
| White et al. [ | 2004 | JAIDS | STDSIM | Heterosexual adults in Rakai and Masaka, Uganda and Mwanza, Tanzania | No | STD treatment |
| White et al. [ | 2008 | AIDS | STDSIM | Heterosexual adults in Sub-Saharan Africa | No | Male circumcision |
| Wilson et al. [ | 2011 | Sex Transm Infect | MSM in Melbourne, Australia | No | Testing |
Evaluation of reporting quality in individual-based models in the HIV transmission and prevention literature (N=32).
|
|
|
|---|---|
|
| |
| 1. Title and Abstract | 32 (100.0) |
| 2. Objective | 30 (93.8) |
| 3. Context | 32 (100.0) |
| 4. Model Justification | 18 (56.3) |
| 5. Structure | 32 (100.0) |
| 6. Assumptions | 32 (100.0) |
| 7. Validity of Sexual Behavior | 32 (100.0) |
| 8. Validity of Biology | 31 (96.9) |
| 9. Parameters | 29 (90.6) |
| 10. Time step | 6 (18.8) |
| 11. Heterogeneity | 25 (78.1) |
| 12. Interaction | 32 (100.0) |
| 13. Calibration | 22 (68.8) |
| 14. Sensitivity Analyses | 29 (90.6) |
| 15. Assumption Sensitivity | 26 (81.3) |
| 16. Stochastic Sensitivity | 15 (46.9) |
| 17. Internal Validity | 1 (3.1) |
| 18. Data Quality | 29 (90.6) |
| 19. Data Conversion | 3 (9.4) |
| 20. Results | 31 (96.9) |
| 21. Limitations and Strengths | 28 (87.5) |
| 22. Reproducibility | 21 (65.6) |
| 23. Discussion | 32 (100.0) |
| 24. Authorship and Funding | 26 (81.3) |
Figure 2Bar chart of the percentage of identified papers that complied with each reporting guideline item.